Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Application of adipose-derived mesenchymal stem cell 3D structure, Microblock, as a skin regeneration therapy.

Park JJ., Seo E., Gwak H., Lee S., Kim J., Lee J.

Animal Study on Chronic Wound, published in Eur J Pharmacol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Eur J Pharmacol (2026)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
41643832
DOI
10.1016/j.ejphar.2026.178637

Abstract (original English)

Adipose-derived mesenchymal stem cells (Ad-MSCs) have been widely studied for their regenerative potential in skin wound healing due to their ability to modulate inflammation, regulate immune responses, promote angiogenesis, and facilitate extracellular matrix (ECM) remodeling. However, the therapeutic efficacy of single-cell transplantation is often limited by low engraftment efficiency and transient effects, restricting its long-term regenerative impact. To overcome these challenges, we developed a spheroid-like structure, Microblock (MiB), designed to enhance the expression of key regenerative proteins compared to conventional single-cell Ad-MSCs. To evaluate its therapeutic potential, we conducted a wound healing assay in a rat model and performed proteomic analysis to investigate its underlying molecular mechanisms. Additionally, a comprehensive non-clinical safety evaluation, including toxicity, tumorigenicity, biodistribution, and persistence studies, was conducted to assess its feasibility for clinical application. Our findings demonstrated that MiB significantly enhanced skin regeneration and tissue remodeling, as evidenced by the upregulation of ECM-related proteins such as Collagen Type I and fibronectin and the activation of TGF-β1 signaling. Furthermore, key TGF-β target proteins associated with VEGFA signaling were identified, and MiB treatment resulted in a subst

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMesenchymal Stem CellsRegenerationSkinWound HealingAdipose TissueRatsMesenchymal Stem Cell TransplantationMaleExtracellular Matrix

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research